Alnylam Pharmaceuticals | ALNY - Ebit


Alnylam Pharmaceuticals reported $137.59M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Arrowhead Research USD -141.26M 182.07M Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Incyte USD 344.17M 39.71M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Moderna USD -1.39B 531M Mar/2026
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novartis USD 4.06B 413M Dec/2025
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Sanofi EUR 3.74B 2.23B Sep/2025
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Takeda JPY -13.62B 271.11B Mar/2026
Tectonic Therapeutic USD -21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026